Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors
Gerhard Niederfellner(Roche (Switzerland)), Klaus Bosslet(University of Giessen), Roland Staak(CS Diagnostics), Frieder Bauss(Roche Pharma AG (Germany)), W. Richter(Evangelisches Krankenhaus Bielefeld), Rita Mateus(Broad Institute), Ira Pastan(National Institutes of Health), Friederike Hesse(University of Cambridge), Gwendlyn Kollmorgen(Roche Pharma AG (Germany)), Ben Krippendorff(CS Diagnostics), Sabine Imhof-Jung, Masanori Onda(National Cancer Institute), Sven Kronenberg(Roche (Switzerland)), Ulli Brinkmann(CS Diagnostics), Martin Lechmann(Roche (Switzerland))
Cited by 4
Related Papers
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
|EMBO Molecular Medicine|2020|411
α-Galactosidase A deficient mice: A model of Fabry disease
|Proceedings of the National Academy of Sciences|1997|370